Biography

Dr. Guvenc Kockaya is currently working as Head of Market Access & Government Affairs at Gilead Turkey and Vice President at Health Economics & Policy Association. He has completed his Ph.D. in Pharmacology and Clinical Pharmacology from Istanbul University, Istanbul, Turkey. Previously he was appointed as Provision Officer at MDS Health, Medical Manager at Farma-Tek Pharmaceuticals, District Rotaract Representative in Rotary International District, Supervision Physician at Duzce 112 Gumusova Ambulance Services, Medical Advisor at Medvice Medical Consultancy, Part-time Lecturer at Yeditepe University, Health Economist at Ministry of Health, General Directorate of Pharmaceutical and Pharmacy, Pharmacoeconomy Department, and Chair of Health Economics Task Force at The Association of Research Based Medical Technologies Manufacturers (ARTED). He has published 63 presentations, 4 books, and 32 research articles in journals contributed as author/co-author. He is also serving as reviewer for many research posters and conferences.

Area of Interest:

Pharmacology and Toxicology

100%

Health

62%

Innovations in Pharmacy

90%

Cardiology

75%

Applied Pharmaceutical Science

55%

Research Publications in Numbers

Books
0

Chapters
0

Articles
0

Abstracts
0

Selected Publications

Ozel, G., G. Kockaya, S. Ozcan, H. Tiner, H. Karadag, R. Kadaifci and Y. Gulhan, 2014. The evaluation of treatment, approach and surgical instrument preferences of surgeons: A survey. Eur. J. Endosci. Laparosci. Surg., 1: 33-39.
Kockaya, G., P.D. Kockaya, O. Ozbagrıacık and S. Oba, 2014. Improving cost‐efficiency at a hospital by showing the time‐saving effect of using different neuromuscular blockers for short operations. J. Pharm. Health Serv. Res., 5: 61-66.
CrossRef | Direct Link |
Kockaya, G., P. Kilic, P. Tanyeri, I.M. Vural, A. Akbulat, G. Artıran and S. Kerman, 2014. A overview of the orphan medicines market in Turkey. Health Regional, 4C: 47-52.
Kockaya, G., F.B. Yenilmez, G. Ergin, K. Atikeler and M. Tatar et al., 2014. Operational Cost of Obesity Surgery in Turkey. Eur. J. Endosci. Laparosc. Surg., 1: 78-83.
Kockaya, G., M. Polat, A. Wertheimer, A. Ozet and S. Malhan et al., 2013. Treatment cost of metastatic colon cancer in Turkey. Farmeconomia. Health Econ. Therap. Pathways, 14: 19-25.
Direct Link |
Vural, E.H., G. Kockaya, P. Tanyeri, S. Babacan and I.M. Vural et al., 2012. Compassionate medicine‐use programmes in Turkey: A report on current status. J. Pharm. Health Serv. Res., 3: 129-134.
CrossRef |
Kockaya, G., P. Tanyeri, P. Kilic, I.M. Vural, A. Akbulat, G. Artıran and S. Kerman, 2012. Consumption budget and price alteration analyses of angiotensin receptor blockers an angiotensin converting enzyme inhibitors in Turkey within Years. Cardiology, 19 : 1-8.
Kockaya, G., P. Tanyeri, M. Vural, A. Akbulat and H. Akar et al., 2012. Off -label and unlicensed endocrionology medicine use in Turkey: A retrospective analysis of computer records in the Turkısh ministry of health. Yedıtepe Med. J., 6: 491-498.
Kockaya, G., B. Ufuktepe, P.D. Kockaya, S. Sen, O. Altunel and A.Y. Uresin, 2012. The efficacy and undesired effects of high dosage zinc treatment. J. Applied Pharmaceut. Sci., 2: 157-159.
Direct Link |
Kockaya, G., P.D. Kockaya and A. Wertheimer, 2011. The cost of neuromuscular blockers in operations of variable length in Turkey. Open Pharmacoecon. Health Econ. J., 3: 1-5.
Direct Link |
Kockaya, G., M. Polat, I.M. Vural, A. Akbulat, B.D. Dedeoglu, H. Akar and S. Kerman, 2011. Off‐label and unlicensed oncology medicine use in Turkey: A retrospective analysis of computer records of the Turkish Ministry of Health. J. Pharmaceut. Health Serv. Res., 2: 53-57.
CrossRef |
Kockaya, G. and A.I. Wertheimer, 2011. An estimation of the effect of 100% compliance with diabetes treatment: Can we reduce cost of illness with higher compliance rates? Innov. Pharm., Vol. 2. .
Direct Link |
Kockaya, G. and A. Wertheimer, 2011. Cost effectiveness analysis of five different treatment alternatives in seasonal allergic conjunctivitis. J. Applied Pharmaceut. Sci., 1: 72-75.
Direct Link |
Kockaya, G. and A. Wertheimer, 2011. Can we reduce the cost of illness with more compliant patients? An estimation of the effect of 100% compliance with hypertension treatment. J. Pharm. Pract., 24: 345-350.
CrossRef | Direct Link |
Kockaya, G. and A. Wertheimer, 2010. Will translational science help reduce costs of illness? Innov. Pharm. .
Direct Link |
Kockaya, G. and A. Wertheimer, 2010. What are the top most costly diseases for USA? The alignment of burden of illness with prevention and screening expenditures. Health, 2: 1174-1178.
CrossRef | Direct Link |
Wertheimer, A. and A. Esen, 2009. Considering the cost-effectiveness of statins in family practice in Turkey from a payer perspective. Health, 1: 274-280.
Direct Link |